Experience

aptaTargets

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder and CFO

  • Mar 2017 - Present

  Madrid y alrededores, España AptaTargets is a biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. AptaTargets is currently developing ApTOLL, an immune modulator which represents a novel approach to treat ischemic stroke in the acute phase by substantially reducing the brain damage. After the successful development in nonclinical stages and First-in-Human trial (Phase I), company is advancing up to a clinical Proof-of-Concept in patients. Additionally, aptaTargets aims… Show more AptaTargets is a biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. AptaTargets is currently developing ApTOLL, an immune modulator which represents a novel approach to treat ischemic stroke in the acute phase by substantially reducing the brain damage. After the successful development in nonclinical stages and First-in-Human trial (Phase I), company is advancing up to a clinical Proof-of-Concept in patients. Additionally, aptaTargets aims to study the use of ApTOLL in other indications where TLR4 receptor plays a key role Show less



Aptus Biotech

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Co-Founder

  • Oct 2010 - Present

  Aptus Biotech is a biotech start-up founded in 2010 from a collaboration agreement with the Ramon y Cajal Hospital Foundation. Our goal is to become a leading start-up in the development of new biotechnological applications based on aptamers. Aptus management and technical team are also supported by Ramon y Cajal Foundation team, with an extensive experience in research and biomedical applications. APTUS Biotech offers aptamer selection services: oligonucleotide Selection by SELEX… Show more Aptus Biotech is a biotech start-up founded in 2010 from a collaboration agreement with the Ramon y Cajal Hospital Foundation. Our goal is to become a leading start-up in the development of new biotechnological applications based on aptamers. Aptus management and technical team are also supported by Ramon y Cajal Foundation team, with an extensive experience in research and biomedical applications. APTUS Biotech offers aptamer selection services: oligonucleotide Selection by SELEX method, aptamer storage through its insertion in bacteria, chemical synthesis of aptamers and binding studies with target proteins. Aptamers are olygonucleotides capable of identifying a target molecule with high affinity and specificity, which grants them enormous potential as therapeutic and diagnostic tools. Show less



Growth Factor Biocapital GFB

• Biotechnology Research

• Partner

  • Jul 2013 - Present

  GFB is an investment platform focused on Spanish biotechnology industry. Our goal is to invest in a portfolio of companies in early-stage development or facing growth.



Leadartis

• Spain
• Research
• 1 - 100 Employee

• Member of the Board

  • Feb 2014 - Mar 2017

  Madrid, Comunidad de Madrid, España LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a… Show more LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer. By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. Trimerbody® is a registered trademark and is covered by international patents. Show less



igen biotech

• Spain
• Biotechnology
• 1 - 100 Employee

• Chief Legal Officer & Chief Administrative Officer

  • Jan 2007 - Mar 2017

  IGEN Biotech is a privately owned company focused on R&D in the biomedical field. Its aim is tovput into practice biomedical research development and bring it to the market as products and services. Its main field is development of new diagnostic methods, drugs and other therapeutic methods, focusing on the use of genomic, proteomic and cell therapy. As a basis of its strategy, IGEN collaborates with R&D centers of reference, both public and private. This results in innovative and… Show more IGEN Biotech is a privately owned company focused on R&D in the biomedical field. Its aim is tovput into practice biomedical research development and bring it to the market as products and services. Its main field is development of new diagnostic methods, drugs and other therapeutic methods, focusing on the use of genomic, proteomic and cell therapy. As a basis of its strategy, IGEN collaborates with R&D centers of reference, both public and private. This results in innovative and quality proposals being added to our projects portfolio. Our goal is to actively participate in the R&D stages, providing research guidelines that will help achieve practical outcomes that can be transformed into innovative goods and services with market demand. Show less



IVI SIGLO XXI

• Legal Advisor

  • May 2004 - Dec 2006

  Real Estate investment funds.